Martina Ferrante
Overview
Explore the profile of Martina Ferrante including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
135
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Benevolo G, Drandi D, Villiva N, Castiglione A, Monaco F, Boccomini C, et al.
Br J Haematol
. 2024 Nov;
206(2):556-564.
PMID: 39604169
This multicentre phase II study Fondazione Italiana Linfomi (FIL)-bortezomib plus rituximab plus bendamustine (BRB) tested a combination of bendamustine (90 mg/m on days 1-2), rituximab (375 mg/m intravenously on day...
2.
Iannitto E, Ferrero S, Bommier C, Drandi D, Ferrante M, Bouabdallah K, et al.
Haematologica
. 2024 Mar;
109(7):2297-2302.
PMID: 38497158
No abstract available.
3.
Tisi M, Moia R, Patti C, Evangelista A, Ferrero S, Spina M, et al.
Blood Adv
. 2023 May;
7(15):3916-3924.
PMID: 37171620
The combination of rituximab, bendamustine, and low-dose cytarabine (R-BAC) has been studied in a phase 2 prospective multicenter study from Fondazione Italiana Linfomi (RBAC500). In 57 previously untreated elderly patients...
4.
Drandi D, Ferrante M, Borriero M, Ferrero S
Methods Mol Biol
. 2023 Apr;
2621:57-72.
PMID: 37041440
MYD88 is a gain-of-function mutation, arising from the missense alteration c.794T>C, that frequently occurs in B-cell malignancies such as Waldenstrom macroglobulinemia and less frequently in IgM monoclonal gammopathy of undetermined...
5.
Dogliotti I, Jimenez C, Varettoni M, Talaulikar D, Bagratuni T, Ferrante M, et al.
Leukemia
. 2022 Nov;
37(2):388-395.
PMID: 36435884
The diagnosis of Waldenström's macroglobulinemia (WM), an IgM-associated lymphoplasmacytic lymphoma, can be challenging due to the different forms of disease presentation. Furthermore, in recent years, WM has witnessed remarkable progress...
6.
Varettoni M, Zibellini S, Merli M, Drandi D, Jimenez C, Furlan D, et al.
Hematol Oncol
. 2022 Oct;
41(3):574-577.
PMID: 36218059
No abstract available.
7.
Parisi M, Dogliotti I, Clerico M, Bertuzzo D, Benevolo G, Orsucci L, et al.
Eur J Neurol
. 2022 Sep;
29(12):3611-3622.
PMID: 36083713
Background And Purpose: We evaluated the clinical and neurophysiological efficacy of rituximab (RTX) in a neurophysiologically homogeneous group of patients with monoclonal gammopathy and immunoglobulin M (IgM) anti-myelin-associated glycoprotein antibody...
8.
Ferrero S, Grimaldi D, Genuardi E, Drandi D, Zaccaria G, Alessandria B, et al.
Blood
. 2022 Jun;
140(12):1378-1389.
PMID: 35737911
Minimal residual disease (MRD) analysis is a known predictive tool in mantle cell lymphoma (MCL). We describe MRD results from the Fondazione Italiana Linfomi phase 3 MCL0208 prospective clinical trial...
9.
Drandi D, Decruyenaere P, Ferrante M, Offner F, Vandesompele J, Ferrero S
Diagnostics (Basel)
. 2022 Apr;
12(4).
PMID: 35454017
Waldenström Macroglobulinemia (WM) is an indolent lymphoplasmacytic lymphoma, characterized by the production of excess immunoglobulin M monoclonal protein. WM belongs to the spectrum of IgM gammopathies, ranging from asymptomatic IgM...
10.
Mantoan B, Genuardi E, Ferrante M, Della Starza I, Ciabatti E, Grassi S, et al.
Hemasphere
. 2021 Sep;
5(10):e639.
PMID: 34514343
No abstract available.